Phase I/II Trial of Combination of Lenalidomide (Revlimid, LEN) and Autologous Mature Dendritic Cells Pulsed With α-galactosyl Ceramide (α-GalCer; KRN7000) in Myeloma

Trial Profile

Phase I/II Trial of Combination of Lenalidomide (Revlimid, LEN) and Autologous Mature Dendritic Cells Pulsed With α-galactosyl Ceramide (α-GalCer; KRN7000) in Myeloma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Feb 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Alpha galactosylceramide; Dendritic cells
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Jun 2016 Status changed from recruiting to completed.
    • 08 May 2009 Actual initiation date (Apr 2009) added as reported by ClinicalTrials.gov.
    • 08 May 2009 Planned end date changed from 1 Aug 2010 to 1 May 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top